Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.45 |
| ▸ | ITGA4 | P13612 | 3/20 | 0.45 |
| ▸ | UBE2N | P61088 | 1/20 | 0.45 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.45 |
| ▸ | YAP1 | P46937 | 2/20 | 0.44 |
| ▸ | CASP3 | P42574 | 4/20 | 0.42 |
| ▸ | PSMB11 | A5LHX3 | 3/20 | 0.41 |
| ▸ | PSMA7 | O14818 | 3/20 | 0.41 |
| ▸ | PSMB1 | P20618 | 3/20 | 0.41 |
| ▸ | PSMA1 | P25786 | 3/20 | 0.41 |
| ▸ | PSMA2 | P25787 | 3/20 | 0.41 |
| ▸ | PSMA3 | P25788 | 3/20 | 0.41 |
| ▸ | PSMA4 | P25789 | 3/20 | 0.41 |
| ▸ | PSMB8 | P28062 | 3/20 | 0.41 |
| ▸ | PSMB9 | P28065 | 3/20 | 0.41 |
| ▸ | PSMA5 | P28066 | 3/20 | 0.41 |
| ▸ | PSMB4 | P28070 | 3/20 | 0.41 |
| ▸ | PSMB6 | P28072 | 3/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL598356 | 1.00 | MAPK1 (0.45) | MAPK1ITGB1ITGA4UBE2NITGB7 | |
| SCHEMBL23230085 | 1.00 | MAPK1 (0.45) | MAPK1ITGB1ITGA4UBE2NITGB7 | |
| SCHEMBL20815350 | 1.00 | MAPK1 (0.45) | MAPK1ITGB1ITGA4UBE2NITGB7 | |
| SCHEMBL29371746 | 1.00 | MAPK1 (0.45) | MAPK1ITGB1ITGA4UBE2NITGB7 | |
| SCHEMBL4648918 | 0.99 | MAPK1 (0.44) | MAPK1ITGB1ITGA4UBE2NITGB7 | |
| SCHEMBL24868206 | 0.95 | ITGB1 (0.50) | MAPK1ITGB1ITGA4ITGB7YAP1 | |
| Potassium Ion SCHEMBL4648916 | 0.94 | UBE2N (0.41) | MAPK1ITGB1ITGA4UBE2NITGB7 | |
| SCHEMBL3744009 | 0.92 | MAPK1 (0.44) | MAPK1ITGB1ITGA4UBE2NITGB7 | |
| SCHEMBL22023402 | 0.92 | MAPK1 (0.44) | MAPK1ITGB1ITGA4UBE2NITGB7 | |
| SCHEMBL6480786 | 0.92 | MAPK1 (0.44) | MAPK1ITGB1ITGA4UBE2NITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1289499-A1 | PHARMACEUTICAL ANTI-INFLAMMATORY AEROSOL FORMULATION | GLAXO GROUP LIMITED (GB) | 2003-03-12 | — | — | EP | claimed |
| EP-1289539-A1 | PHARMACEUTICAL ANTI-INFLAMMATORY AEROSOL FORMULATION | GLAXO GROUP LIMITED (GB) | 2003-03-12 | — | — | EP | claimed |
| WO-2001095881-A1 | PHARMACEUTICAL ANTI-INFLAMMATORY AEROSOL FORMULATION | GLAXO GROUP LIMITED (GB) | 2001-12-20 | — | — | WO | claimed |
| WO-2001095925-A1 | PHARMACEUTICAL ANTI-INFLAMMATORY AEROSOL FORMULATION | GLAXO GROUP LIMITED (GB) | 2001-12-20 | — | — | WO | claimed |
| US-20240158375-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2024-05-16 | — | — | US | disclosed |
| US-20230357207-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | BCP3 PTY LIMITED (AU) | 2023-11-09 | — | — | US | disclosed |
| EP-4232458-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | AZURA OPHTHALMICS LTD (IL) | 2023-08-30 | — | — | EP | disclosed |
| CN-116670116-A | Compounds and methods for treating ocular disorders | 阿祖拉眼科有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-11634411-B2 | Compounds and methods for the treatment of ocular disorders | Azura Ophthalmics Ltd. (IL) | 2023-04-25 | — | — | US | disclosed |
| US-20230033021-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN INTEGRIN INHIBITOR | GLAS USA LLC | 2023-02-02 | — | — | US | disclosed |
| WO-2022084747-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2022-04-28 | — | — | WO | disclosed |
| EP-3955926-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2022-02-23 | — | — | EP | disclosed |
| EP-1455872-A2 | METHOD AND APPARATUS FOR TESTING A METERED DOSE INHALER UNIT | GLAXO GROUP LIMITED (GB) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003055539-A2 | METHOD AND APPARATUS FOR TESTING A METERED DOSE INHALER UNIT | GLAXO GROUP LIMITED (GB) | 2003-07-10 | — | — | WO | disclosed |
| EP-1289500-A1 | NOVEL PHARMACEUTICAL FORMULATION SUITABLE FOR NEBULISATION | GLAXO GROUP LIMITED (GB) | 2003-03-12 | — | — | EP | disclosed |
| EP-1289498-A1 | NOVEL PHARMACEUTICAL FORMULATION SUITABLE FOR NEBULISATION | GLAXO GROUP LIMITED (GB) | 2003-03-12 | — | — | EP | disclosed |
| EP-1289499-A1 | PHARMACEUTICAL ANTI-INFLAMMATORY AEROSOL FORMULATION | GLAXO GROUP LIMITED (GB) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001095883-A1 | NOVEL PHARMACEUTICAL FORMULATION SUITABLE FOR NEBULISATION | GLAXO GROUP LIMITED (GB) | 2001-12-20 | — | — | WO | disclosed |
| WO-2001095880-A1 | NOVEL PHARMACEUTICAL FORMULATION SUITABLE FOR NEBULISATION | GLAXO GROUP LIMITED (GB) | 2001-12-20 | — | — | WO | disclosed |
| WO-2001095881-A1 | PHARMACEUTICAL ANTI-INFLAMMATORY AEROSOL FORMULATION | GLAXO GROUP LIMITED (GB) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158375-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | MPO, MUC1, CRYAB | MAPK1 3356/4885ITGB1 1385/4885ITGA4 1271/4885 |
| US-20230033021-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN INTEGRIN INHIBITOR | ITGAL, ITGB2, ITGB1 | MAPK1 1155/4885ITGB1 3/4885ITGA4 17/4885 |
| US-11634411-B2 | Compounds and methods for the treatment of ocular disorders | MUC1, MPO, SERPINB1 | MAPK1 3501/4885ITGB1 1239/4885ITGA4 1078/4885 |
| US-20230357207-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | MUC1, MPO, SERPINB1 | MAPK1 3501/4885ITGB1 1239/4885ITGA4 1078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.